Clinical outcomes and safety of adjuvant therapy in patients with high-risk melanoma harboring BRAF V600 mutations: A multicenter, retrospective cohort study. Lymphatic mapping to the inguinal region ...
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier ...
The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...
Neoadjuvant immunotherapy in clinical stage III melanoma: Real life experience in the community setting. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCCmaMICVO ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
PD-1 inhibitors may raise heart failure risk in patients with prior ischaemia. Discover key findings and clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results